Literature DB >> 6781873

Geometric isomers of substituted triphenylethylenes and antiestrogen action.

V C Jordan, B Haldemann, K E Allen.   

Abstract

The estrogenic and antiestrogenic activities of tamoxifen ICI 47,699, enclomiphene, zuclomiphene, and the geometric isomers of monohydroxytamoxifen and CI628 were determined in the 3-day immature rat uterine weight test. Tamoxifen, enclomiphene, and the releated geometric isomers of monohydroxytamoxifen and CI628 were partially estrogenic with antiestrogenic properties. ICI 47,699 and zuclomiphene were predominantly estrogenic; however, an antiestrogen effect for zuclomiphene (100 micrograms daily) was demonstrable and large doses of ICI 47,699 (1 or 10 mg daily) inhibited full estrogen action. In contrast, the geometric isomers of monohydroxytamoxifen and CI628 related to ICI 47,699 and zuclomiphene were partially estrogenic with antiestrogenic properties. The estrogenic properties of ICI 47,699 were classified in three ways: elevation of uterine wet weight, increase in whole uterine DNA, and increase in the mitotic activity of luminal epithelial cells. In general, ICI 47,699 was able to initiate estrogenic responses of DNA synthesis or mitosis by translocation of fewer cytoplasmic estrogen receptors to the nuclear compartment than tamoxifen. A model is proposed to explain antiestrogen action in terms of the geometric requirements for receptor binding. It is suggested that the position in space of the alkylaminoethoxyside chain is of fundamental importance. Overall, these data lend support to the view that a structurally specific ligand-estrogen receptor complex can influence the future events within a target tissue to produce either an agonist or an antagonist response.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6781873     DOI: 10.1210/endo-108-4-1353

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Biochemical and pharmacological effects of toremifene metabolites.

Authors:  L Kangas
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Acetoxy substituted 1,1,2-triphenylbut-1-enes: estrogenic, antiestrogenic and mammary tumor inhibiting activity.

Authors:  M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

4.  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.

Authors:  Pia Wegman; Sauli Elingarami; John Carstensen; Olle Stål; Bo Nordenskjöld; Sten Wingren
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 5.  Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.

Authors:  V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2021-08-16       Impact factor: 4.872

Review 6.  Structure-activity relationships of estrogens.

Authors:  V C Jordan; S Mittal; B Gosden; R Koch; M E Lieberman
Journal:  Environ Health Perspect       Date:  1985-09       Impact factor: 9.031

7.  Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.

Authors:  Philipp Y Maximov; Daphne J Fernandes; Russell E McDaniel; Cynthia B Myers; Ramona F Curpan; V Craig Jordan
Journal:  J Med Chem       Date:  2014-05-22       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.